ZENAS BIOPHARMA INC
ZBIONASDAQTrading Snapshot
- Day Range
- $553.12 – $571.83
- 52-Week Range
- $13.50 – $44.60
- Volume
- $2.42B
- Avg Volume
- $1.90B
- Shares Outstanding
- 63.1M
- Next Earnings
- Nov 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $1M
- P/E Ratio
- -2.9
- P/S Ratio
- 1739.3x
- EPS (TTM)
- $-7.67
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +11.3%
Why Investors Own ZBIO
- ✓High-growth profile — revenue up +23.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ZENAS BIOPHARMA INC
ZBIO
StockOtter · stockotter.spaceAbout ZENAS BIOPHARMA INC
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
ZENAS BIOPHARMA INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ZBIO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ZENAS BIOPHARMA INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.